Cancer Drug Shows Promise in Clinical Trial Results
New therapy combined with standard care shows positive response rates in metastatic colorectal cancer patients.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Do you trust that new cancer treatments are being adequately tested for safety before widespread use?
Results from the INCA33890-101 clinical trial demonstrate promising response rates for patients with metastatic microsatellite stable colorectal cancer. The experimental drug targets TGF-β and PD-1 signaling pathways to improve antitumor immunity.
Why it matters
TGF-β signaling in the tumor microenvironment often limits the effectiveness of traditional immunotherapy. By blocking these signals, the drug aims to enhance treatment outcomes for patients with historically harder-to-treat cancer.
The trial reported a 71.4% objective response rate for first-line patients and 28.2% for third-line patients, with no dose-limiting toxicities observed at the 900 mg dosage. However, 72.1% of patients in the primary study cohort experienced grade 3 or higher adverse effects.
The players
ESMO Congress
This is a major international medical conference where oncology researchers present and discuss the latest findings in cancer treatment and clinical research.
The details
The drug INCA33890 works by blocking signaling through TGF-β receptor 2 and PD-1 in PD-1-positive T cells. Researchers are now expanding this investigation into the phase 3 NEXERA-303 trial to confirm efficacy against placebo-controlled standards.
Timeline
March 5, 2026: The phase 3 NEXERA-303 trial opened for patient recruitment.
October 23-27, 2026: Study results were presented at the 2026 ESMO Congress in Madrid.
December 29, 2028: The NEXERA-303 trial has an estimated primary completion date.
The Big Picture
The NEXERA-303 clinical trial sets a new standard for testing combined immunotherapies in microsatellite stable colorectal cancer. This research marks a departure from legacy monotherapy approaches by targeting the immunosuppressive tumor microenvironment directly.
These trial results offer a potential new therapeutic pathway for patients who may not have responded to standard chemotherapy alone. Patients should consult with their oncologists to understand how these emerging clinical trial options fit into their specific treatment plans.
The takeaway
These findings highlight a significant evolution in how researchers approach the tumor microenvironment to improve cancer drug efficacy. Patients and families can monitor the ongoing phase 3 trial for future updates on treatment availability.
What happens next
The phase 3 NEXERA-303 trial, which aims to enroll 700 patients, is scheduled to reach its estimated primary completion date on December 29, 2028.
Further reading
Learn more about evolving treatment protocols at the Cancer section.
More information
Review the full study protocol and eligibility criteria in the NEXERA-303 clinical trial registration.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new cancer treatments are being adequately tested for safety before widespread use?
